[go: up one dir, main page]

WO2009149278A8 - Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles - Google Patents

Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles Download PDF

Info

Publication number
WO2009149278A8
WO2009149278A8 PCT/US2009/046287 US2009046287W WO2009149278A8 WO 2009149278 A8 WO2009149278 A8 WO 2009149278A8 US 2009046287 W US2009046287 W US 2009046287W WO 2009149278 A8 WO2009149278 A8 WO 2009149278A8
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
disorders
gastrointestinal
inflammation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/046287
Other languages
English (en)
Other versions
WO2009149278A1 (fr
Inventor
Kunwar Shailubhai
Gary S. Jacob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synergy Pharmaceuticals Inc
Original Assignee
Synergy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergy Pharmaceuticals Inc filed Critical Synergy Pharmaceuticals Inc
Priority to EP09759437.8A priority Critical patent/EP2296685B1/fr
Priority to ES09759437.8T priority patent/ES2559840T3/es
Priority to CA2726913A priority patent/CA2726913C/fr
Priority to AU2009256156A priority patent/AU2009256156B2/en
Priority to JP2011512657A priority patent/JP2011523662A/ja
Priority to HK11109460.9A priority patent/HK1155092B/en
Publication of WO2009149278A1 publication Critical patent/WO2009149278A1/fr
Publication of WO2009149278A8 publication Critical patent/WO2009149278A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux peptides agonistes de guanylase cyclase-C et leur utilisation dans le traitement de maladies humaines telles que les troubles gastro-intestinaux, l'inflammation ou le cancer (par exemple, un cancer gastro-intestinal). Les peptides peuvent être administrés soit seuls, soit en combinaison avec un inhibiteur de phosphodiestérase dépendant de GMPc. Le trouble gastro-intestinal peut être classifié comme syndrome du côlon irritable, constipation, ou acidité excessive, etc. La maladie gastro-intestinale peut être classifiée comme affection abdominale inflammatoire ou autre affection gastro-intestinale, telle que la maladie de Crohn, la colite ulcérative ou le cancer.
PCT/US2009/046287 2008-06-04 2009-06-04 Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles Ceased WO2009149278A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP09759437.8A EP2296685B1 (fr) 2008-06-04 2009-06-04 Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
ES09759437.8T ES2559840T3 (es) 2008-06-04 2009-06-04 Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2726913A CA2726913C (fr) 2008-06-04 2009-06-04 Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
AU2009256156A AU2009256156B2 (en) 2008-06-04 2009-06-04 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011512657A JP2011523662A (ja) 2008-06-04 2009-06-04 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
HK11109460.9A HK1155092B (en) 2008-06-04 2009-06-04 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5888808P 2008-06-04 2008-06-04
US61/058,888 2008-06-04

Publications (2)

Publication Number Publication Date
WO2009149278A1 WO2009149278A1 (fr) 2009-12-10
WO2009149278A8 true WO2009149278A8 (fr) 2010-04-22

Family

ID=41026379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/046287 Ceased WO2009149278A1 (fr) 2008-06-04 2009-06-04 Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles

Country Status (7)

Country Link
US (4) US8207295B2 (fr)
EP (1) EP2296685B1 (fr)
JP (1) JP2011523662A (fr)
AU (1) AU2009256156B2 (fr)
CA (1) CA2726913C (fr)
ES (1) ES2559840T3 (fr)
WO (1) WO2009149278A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330312T5 (es) 2001-03-29 2014-01-31 Synergy Pharmaceuticals, Inc. Agonistas de receptor de guanilato ciclasa para el tratamiento de la inflamación de tejidos y de la carcionogénesis
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2726913C (fr) 2008-06-04 2020-02-25 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010065751A2 (fr) * 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation
US8575087B2 (en) 2009-05-30 2013-11-05 The University Of Toledo Treatment of cancers with A-8R peptide
US9301991B2 (en) 2009-05-30 2016-04-05 The University Of Toledo sGCalphal inhibiting compositions
WO2011050242A1 (fr) 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Molécules d'anticorps anti-gcc, compositions et procédés apparentés
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
MA33984B1 (fr) * 2010-02-05 2013-02-01 Bayer Ip Gmbh Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique
JP6393037B2 (ja) 2010-09-15 2018-09-19 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤および使用方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2681236B1 (fr) 2011-03-01 2018-01-03 Synergy Pharmaceuticals Inc. Procédé de préparation d'agonistes du guanylate cyclase c
SI2841575T1 (sl) 2012-04-27 2019-11-29 Millennium Pharm Inc Molekule anti-GCC protitelesa in uporaba le-teh za preskušanje dovzetnosti za GCC-ciljno terapijo
CA2902348C (fr) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et applications associees
EP2968439A2 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
KR20220147691A (ko) * 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CN106061494A (zh) * 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
WO2015066285A2 (fr) * 2013-11-01 2015-05-07 The University Of Toledo Compositions inhibant sgcα1 et méthodes de traitement de cancers à l'aide desdites compositions
CA3009814A1 (fr) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations et methodes pour traiter la rectocolite hemorragique
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3972599B1 (fr) 2019-05-21 2025-10-22 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969097A (en) * 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
DE69433523T2 (de) * 1993-03-09 2004-12-23 Baxter International Inc., Deerfield Makromolekulare Mikropartikel und Verfahren zur ihrer Herstellung
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5601990A (en) * 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
AU681920B2 (en) * 1993-10-26 1997-09-11 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5518888A (en) * 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6203513B1 (en) 1997-11-20 2001-03-20 Optonol Ltd. Flow regulating implant, method of manufacture, and delivery device
US6235782B1 (en) * 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
DE19903087A1 (de) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
EP1220872A1 (fr) 1999-10-06 2002-07-10 Pharmacia Corporation Uroguanyline, anticancereux intestinal
JP4088412B2 (ja) * 2000-12-26 2008-05-21 トヨタ自動車株式会社 内燃機関の空燃比制御装置
WO2002062369A2 (fr) 2001-02-02 2002-08-15 Pharmacia Corporation Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
WO2002074052A2 (fr) 2001-03-16 2002-09-26 Glaukos Corporation Applicateur et procedes de mise en place de derivation trabeculaire pour traiter un glaucome
ES2330312T5 (es) 2001-03-29 2014-01-31 Synergy Pharmaceuticals, Inc. Agonistas de receptor de guanilato ciclasa para el tratamiento de la inflamación de tejidos y de la carcionogénesis
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
DE10292434D2 (de) * 2001-06-05 2004-07-29 Yueksel Savas Verwendung eines Peptids, welches Guanylat Cyclase C aktiviert, für die Behandlung von Atemwegserkrankungen über die Luftwege, Arzneimittel, Inhalationsvorrichtung und Diagnoseverfahren
US6991726B2 (en) * 2002-07-01 2006-01-31 Usfilter Corporation Filter having a media retaining plate
ATE419026T1 (de) 2002-07-19 2009-01-15 Univ Yale Uveosklerale drainagevorrichtung
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BR122018074353B8 (pt) 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7073363B2 (en) * 2003-05-20 2006-07-11 Schumag Ag Method for processing drawn material and drawn material production installation
ES2391974T3 (es) * 2003-06-13 2012-12-03 Ironwood Pharmaceuticals, Inc. Procedimientos y composiciones para el tratamiento de trastornos gastrointestinales
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
CA2540678C (fr) * 2003-09-30 2011-02-22 New River Pharmaceuticals Inc. Compositions pharmaceutiques pour prevenir une dose excessive ou un abus
US7291125B2 (en) 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
TWI536429B (zh) * 2004-11-18 2016-06-01 尼康股份有限公司 A position measuring method, a position control method, a measuring method, a loading method, an exposure method and an exposure apparatus, and a device manufacturing method
DE102004062773A1 (de) 2004-12-21 2006-06-22 Röhm GmbH & Co. KG Beschichtungsmittel zur Herstellung von umformbaren Kratzfestbeschichtungen mit schmutzabweisender Wirkung, kratzfeste umformbare schmutzabweisende Formkörper sowie Verfahren zu deren Herstellung
EP1940441A4 (fr) 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc Compositions et methodes de traitement de troubles gastro-intestinaux
US20070101158A1 (en) * 2005-10-28 2007-05-03 Elliott Robert C Security region in a non-volatile memory
WO2007101158A2 (fr) 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Méthodes et compositions servant au traitement de troubles gastro-intestinaux
US7692307B2 (en) * 2006-12-08 2010-04-06 Intel Corporation Compliant structure for an electronic device, method of manufacturing same, and system containing same
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
RU2009144972A (ru) * 2007-05-04 2011-06-10 Айронвуд Фармасьютикалз, Инк. (Us) Композиции и способы лечения нарушений, ассоциированных с задержкой соли или жидкости
ES2559319T3 (es) * 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2726913C (fr) 2008-06-04 2020-02-25 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010065751A2 (fr) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation

Also Published As

Publication number Publication date
US20130274204A1 (en) 2013-10-17
CA2726913C (fr) 2020-02-25
JP2011523662A (ja) 2011-08-18
US20120220526A1 (en) 2012-08-30
HK1155092A1 (zh) 2012-05-11
AU2009256156B2 (en) 2014-09-18
EP2296685B1 (fr) 2015-09-02
US8357775B2 (en) 2013-01-22
WO2009149278A1 (fr) 2009-12-10
US8497348B2 (en) 2013-07-30
EP2296685A1 (fr) 2011-03-23
US8207295B2 (en) 2012-06-26
CA2726913A1 (fr) 2009-12-10
ES2559840T3 (es) 2016-02-16
US20130096071A1 (en) 2013-04-18
AU2009256156A1 (en) 2009-12-10
US20100069306A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
WO2010009319A3 (fr) Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2009149278A8 (fr) Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2008151257A3 (fr) Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
WO2009149279A3 (fr) Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010065751A3 (fr) Formulations d'agonistes de guanylate cyclase c et méthode d'utilisation
WO2012037380A3 (fr) Préparations d'agonistes du guanylate cyclase-c et méthodes d'utilisation
EP4309673A3 (fr) Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation
WO2009007849A3 (fr) Antagonistes du récepteur de l'il-23 et leurs utilisations
WO2010029089A3 (fr) Polythérapie pour le traitement du diabète et des états pathologiques apparentés
WO2007112288A3 (fr) Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer
WO2007056681A3 (fr) Procedes d'administration d'agents hypoglycemiques
WO2008153705A3 (fr) Procédés de traitement, de diagnostic et de détection de troubles liés à fgf21
EP2500362A3 (fr) Anticorps humanisés contre TL1A
WO2007133731A3 (fr) Composés de ligand de créatine et procédés d'utilisation correspondants
WO2009109927A3 (fr) Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
WO2007092936A3 (fr) Procédé pour traiter des lésions gastriques
WO2008043107A3 (fr) Utilisation d'antagonistes des jonctions occlusives pour traiter les affections abdominales inflammatoires
TN2009000095A1 (en) Thiazole pyrazolopyrimidines as crf1 receptor antagonists
WO2008075040A3 (fr) Agents d'imagerie in vivo
WO2008033987A3 (fr) Compositions et procédés de prévention du cancer avec des cupredoxines
WO2009114756A3 (fr) Biomarqueurs pour maladie intestinale inflammatoire et syndrome du côlon irritable
WO2007141284A3 (fr) Antagonistes du peptide cgrp
WO2012019188A3 (fr) Procédés et compositions destinés à l'inhibition de la fructokinase
WO2009018226A3 (fr) Combinaisons pharmaceutiques
WO2012006056A3 (fr) Ccr6 en tant que biomarqueur de la maladie d'alzheimer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09759437

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2726913

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011512657

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009256156

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009759437

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009256156

Country of ref document: AU

Date of ref document: 20090604

Kind code of ref document: A